creatine has been researched along with Breast Neoplasms in 29 studies
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER-2) negative (HR+/HER2-) advanced breast cancer (ABC), especially with bone metastasis." | 8.31 | Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2- advanced breast cancer. ( Bai, X; Hao, C; Meng, W; Tong, Z; Zhang, J, 2023) |
| "The growth-inhibitory effect of cyclocreatine (CCr) and the kinetics of CCr and Na(+) cotransport were investigated in MCF7 human breast cancer cells and its adriamycin-resistant subline with use of (31)P- and (23)Na-NMR spectroscopy." | 7.70 | Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity. ( Cohn, M; Degani, H; Maril, N; Rushkin, E; Sherry, AD, 1999) |
| "The hydroxyproline/creatinine excretion ratios have been measured in half-hour fasting morning urine specimens from breast cancer patients and compared with corresponding values measured in 24 hour urine collections." | 7.65 | Early morning hydroxyproline excretion in patients with breast cancer. ( Bondy, PK; Leese, CL; Powles, TJ; Rosset, G, 1976) |
| "Obesity is a major risk factor for adverse outcomes in breast cancer; however, the underlying molecular mechanisms have not been elucidated." | 5.62 | Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. ( Ackerman, SE; Annis, MG; Carroll, TS; Ceballos, V; Cohen, P; Dannenberg, AJ; Dykstra, CB; Gelfer, RG; Hejazi, A; Huang, X; Jiang, CS; Kazak, L; Kramer, DJ; Luo, JD; Maganti, AV; Maguire, OA; Marchildon, F; Mirmira, RG; Rahbani, JF; Rosas-Villegas, A; Samborska, B; Siegel, PM; Szwed, SK; Tersey, SA; Turner, LE, 2021) |
| "Metastasis is the major cause for breast cancer related mortality." | 5.51 | Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. ( Fernandez, CA; Ho, PY; Li, S; Luo, Z; Ma, W; Rathod, SB; Sun, J; Venkataramanan, R; Xie, W; Xu, J; Yu, AM; Zhao, W, 2019) |
| "Breast tumors are characterized into subtypes based on their surface marker expression, which affects their prognosis and treatment." | 5.43 | The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells. ( Bao, X; Bhute, VJ; Ma, Y; Palecek, SP, 2016) |
| "It was concluded that in brain metastases of mammary carcinoma Lact represents a product of ischemia preceding/during tissue decay resulting in central necrosis, rather than tumor specific metabolism resulting in increased glycolysis." | 5.29 | Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. ( Oudkerk, M; Sijens, PE; van Dijk, P, 1994) |
| "Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER-2) negative (HR+/HER2-) advanced breast cancer (ABC), especially with bone metastasis." | 4.31 | Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2- advanced breast cancer. ( Bai, X; Hao, C; Meng, W; Tong, Z; Zhang, J, 2023) |
| "Eight patients with advanced breast cancer were entered into a prospective, longitudinal trial that included examination by MR imaging and proton MR spectroscopy before chemotherapy and through 12 months after treatment with carmustine, cyclophosphamide, and cisplatin, combined with autologous hematopoietic progenitor cell support (AHPCS)." | 3.70 | White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. ( Brown, MS; Cagnoni, PJ; Jones, RB; Sheeder, JL; Simon, JH; Stears, JC; Stemmer, SM, 1998) |
| "The growth-inhibitory effect of cyclocreatine (CCr) and the kinetics of CCr and Na(+) cotransport were investigated in MCF7 human breast cancer cells and its adriamycin-resistant subline with use of (31)P- and (23)Na-NMR spectroscopy." | 3.70 | Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity. ( Cohn, M; Degani, H; Maril, N; Rushkin, E; Sherry, AD, 1999) |
| "The hydroxyproline/creatinine excretion ratios have been measured in half-hour fasting morning urine specimens from breast cancer patients and compared with corresponding values measured in 24 hour urine collections." | 3.65 | Early morning hydroxyproline excretion in patients with breast cancer. ( Bondy, PK; Leese, CL; Powles, TJ; Rosset, G, 1976) |
| "Creatine is a nitrogen-containing organic acid naturally existing in mammals." | 2.82 | The two sides of creatine in cancer. ( Bu, P; Zhang, L, 2022) |
| "Obesity is a major risk factor for adverse outcomes in breast cancer; however, the underlying molecular mechanisms have not been elucidated." | 1.62 | Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. ( Ackerman, SE; Annis, MG; Carroll, TS; Ceballos, V; Cohen, P; Dannenberg, AJ; Dykstra, CB; Gelfer, RG; Hejazi, A; Huang, X; Jiang, CS; Kazak, L; Kramer, DJ; Luo, JD; Maganti, AV; Maguire, OA; Marchildon, F; Mirmira, RG; Rahbani, JF; Rosas-Villegas, A; Samborska, B; Siegel, PM; Szwed, SK; Tersey, SA; Turner, LE, 2021) |
| "Metastasis is the major cause for breast cancer related mortality." | 1.51 | Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis. ( Fernandez, CA; Ho, PY; Li, S; Luo, Z; Ma, W; Rathod, SB; Sun, J; Venkataramanan, R; Xie, W; Xu, J; Yu, AM; Zhao, W, 2019) |
| "Breast tumors are characterized into subtypes based on their surface marker expression, which affects their prognosis and treatment." | 1.43 | The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells. ( Bao, X; Bhute, VJ; Ma, Y; Palecek, SP, 2016) |
| "By using the Tanaka equation, breast cancer in women is more prevalent in group 2 (1." | 1.40 | Estimated amount of 24-hour urine sodium excretion is positively correlated with stomach and breast cancer prevalence in Korea. ( Chin, HJ; Kim, S; Kim, YC; Koo, HS; Oh, SW; Park, JH, 2014) |
| "The survival of breast cancer patients has significantly improved through the treatment with anthracyclines." | 1.32 | Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy. ( Králícková, P; Malír, F; Melichar, B; Roubal, T, 2004) |
| "In patients with breast cancer and skin metastases, topically applied miltefosine solution yields at least partial regression of the lesions in approximately a quarter of patients when used as an adjunct to standard treatment (surgery, radiotherapy, systemic chemotherapy or hormone therapy) or when standard treatments are contraindicated." | 1.30 | Miltefosine: new preparation. Solution for cutaneous application. ( , 1998) |
| "It was concluded that in brain metastases of mammary carcinoma Lact represents a product of ischemia preceding/during tissue decay resulting in central necrosis, rather than tumor specific metabolism resulting in increased glycolysis." | 1.29 | Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. ( Oudkerk, M; Sijens, PE; van Dijk, P, 1994) |
| "In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer." | 1.24 | HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 7 (24.14) | 18.2507 |
| 2000's | 1 (3.45) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 5 (17.24) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 2 |
| Bu, P | 2 |
| Hao, C | 1 |
| Bai, X | 1 |
| Zhang, J | 1 |
| Meng, W | 1 |
| Tong, Z | 1 |
| Beyer, J | 1 |
| Couch, R | 1 |
| Ruddy, KJ | 1 |
| Zeydan, B | 1 |
| Tosakulwong, N | 1 |
| Lesnick, TG | 1 |
| Novotny, PJ | 1 |
| Kohli, S | 1 |
| Cerhan, JH | 1 |
| Pruthi, S | 1 |
| Kantarci, K | 1 |
| Kara, F | 1 |
| Maguire, OA | 1 |
| Ackerman, SE | 1 |
| Szwed, SK | 1 |
| Maganti, AV | 1 |
| Marchildon, F | 1 |
| Huang, X | 1 |
| Kramer, DJ | 1 |
| Rosas-Villegas, A | 1 |
| Gelfer, RG | 1 |
| Turner, LE | 1 |
| Ceballos, V | 1 |
| Hejazi, A | 1 |
| Samborska, B | 1 |
| Rahbani, JF | 1 |
| Dykstra, CB | 1 |
| Annis, MG | 1 |
| Luo, JD | 1 |
| Carroll, TS | 1 |
| Jiang, CS | 1 |
| Dannenberg, AJ | 1 |
| Siegel, PM | 1 |
| Tersey, SA | 1 |
| Mirmira, RG | 1 |
| Kazak, L | 1 |
| Cohen, P | 1 |
| Zhu, Z | 1 |
| Yan, H | 1 |
| Wang, W | 1 |
| Wu, Z | 1 |
| Zhang, F | 1 |
| Zhang, Q | 1 |
| Shi, G | 1 |
| Du, J | 1 |
| Cai, H | 1 |
| Zhang, X | 1 |
| Hsu, D | 1 |
| Gao, P | 1 |
| Piao, HL | 1 |
| Chen, G | 1 |
| Ben-Sahra, I | 1 |
| Puissant, A | 1 |
| Xu, J | 1 |
| Sun, J | 1 |
| Ho, PY | 1 |
| Luo, Z | 1 |
| Ma, W | 1 |
| Zhao, W | 1 |
| Rathod, SB | 1 |
| Fernandez, CA | 1 |
| Venkataramanan, R | 1 |
| Xie, W | 1 |
| Yu, AM | 1 |
| Li, S | 1 |
| Zick, SM | 1 |
| Zwickey, H | 1 |
| Wood, L | 1 |
| Foerster, B | 1 |
| Khabir, T | 1 |
| Wright, B | 1 |
| Ichesco, E | 1 |
| Sen, A | 1 |
| Harris, RE | 1 |
| Park, JH | 1 |
| Kim, YC | 1 |
| Koo, HS | 1 |
| Oh, SW | 1 |
| Kim, S | 1 |
| Chin, HJ | 1 |
| Bhute, VJ | 1 |
| Ma, Y | 1 |
| Bao, X | 1 |
| Palecek, SP | 1 |
| Devore, EE | 1 |
| Warner, ET | 1 |
| Eliassen, AH | 1 |
| Brown, SB | 1 |
| Beck, AH | 1 |
| Hankinson, SE | 1 |
| Schernhammer, ES | 1 |
| SEGALOFF, A | 2 |
| HORWITT, BN | 1 |
| CARABASI, RA | 1 |
| MURISON, PJ | 1 |
| SCHLOSSER, JV | 1 |
| CUNINGHAM, M | 1 |
| WEETH, JB | 1 |
| RONGONE, EL | 1 |
| MEYER, KK | 1 |
| GARDNER, B | 2 |
| GRAHAM, WP | 2 |
| GORDAN, GS | 2 |
| LOKEN, HF | 1 |
| THOMAS, AN | 1 |
| TEAL, JS | 1 |
| HAHNEMANN, S | 1 |
| FRIIS, T | 1 |
| STERN, E | 1 |
| HOPKINS, CE | 1 |
| WEINER, JM | 1 |
| MARMORSTON, J | 1 |
| Králícková, P | 1 |
| Melichar, B | 1 |
| Malír, F | 1 |
| Roubal, T | 1 |
| Davis, FB | 1 |
| Sijens, PE | 1 |
| van Dijk, P | 1 |
| Oudkerk, M | 1 |
| Bergnes, G | 1 |
| Yuan, W | 1 |
| Khandekar, VS | 1 |
| O'Keefe, MM | 1 |
| Martin, KJ | 1 |
| Teicher, BA | 1 |
| Kaddurah-Daouk, R | 1 |
| Brown, MS | 1 |
| Stemmer, SM | 1 |
| Simon, JH | 1 |
| Stears, JC | 1 |
| Jones, RB | 1 |
| Cagnoni, PJ | 1 |
| Sheeder, JL | 1 |
| Malycha, P | 1 |
| Mountford, C | 1 |
| Maril, N | 1 |
| Degani, H | 1 |
| Rushkin, E | 1 |
| Sherry, AD | 1 |
| Cohn, M | 1 |
| Waalkes, TP | 1 |
| Tormey, DC | 1 |
| Powles, TJ | 1 |
| Rosset, G | 1 |
| Leese, CL | 1 |
| Bondy, PK | 1 |
| Gallacher, SJ | 1 |
| Fraser, WD | 1 |
| Patel, U | 1 |
| Logue, FC | 1 |
| Soukop, M | 1 |
| Boyle, IT | 1 |
| Ralston, SH | 1 |
| Guzzo, CE | 1 |
| Pachas, WN | 1 |
| Pinals, RS | 1 |
| Krant, MJ | 1 |
2 reviews available for creatine and Breast Neoplasms
| Article | Year |
|---|---|
The two sides of creatine in cancer.
Topics: Animals; Breast Neoplasms; Creatine; Female; Humans; Mammals; Mice; Phosphocreatine | 2022 |
Biologic markers and breast cancer.
Topics: alpha-Macroglobulins; Blood Proteins; Breast Neoplasms; Calcitonin; Carbohydrates; Carcinoembryonic | 1978 |
27 other studies available for creatine and Breast Neoplasms
| Article | Year |
|---|---|
Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2- advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Creatine; Creatinine; Diphosphonat | 2023 |
Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study.
Topics: Aspartic Acid; Brain; Breast Neoplasms; Choline; Cognition; Creatine; Female; Gyrus Cinguli; Humans | 2023 |
Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer.
Topics: Adipose Tissue; Amidinotransferases; Animals; Breast Neoplasms; Cell Communication; Cell Line, Tumor | 2021 |
Creatine promotes cancer metastasis through activation of Smad2/3.
Topics: Animals; Breast Neoplasms; Cell Line; Colorectal Neoplasms; Creatine; Dietary Supplements; Female; H | 2021 |
HER2 Signaling Hijacks the Creatine Shuttle to Fuel Breast Cancer Cell Growth.
Topics: Breast Neoplasms; Creatine; Creatine Kinase, Mitochondrial Form; Humans; Phosphorylation; Receptor, | 2018 |
Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Bioengineering; Breast Neoplasms; Cell Line, Tumor; Creatine; Down-R | 2019 |
Preliminary differences in peripheral immune markers and brain metabolites between fatigued and non-fatigued breast cancer survivors: a pilot study.
Topics: Aspartic Acid; Biomarkers; Brain; Breast Neoplasms; Creatine; Cross-Sectional Studies; Fatigue; Fema | 2014 |
Estimated amount of 24-hour urine sodium excretion is positively correlated with stomach and breast cancer prevalence in Korea.
Topics: Adult; Aged; Algorithms; Breast Neoplasms; Creatine; Demography; Female; Humans; Male; Middle Aged; | 2014 |
The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
Topics: Amino Acids; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Creatine; DNA Damage; Female; Gluta | 2016 |
Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.
Topics: Aged; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Creatine; Female; Humans; Incidence | 2017 |
Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion.
Topics: Androgens; Breast; Breast Neoplasms; Creatine; Humans; Methyltestosterone; Neoplasms; Urine | 1953 |
HORMONAL THERAPY IN CANCER OF THE BREAST. XXII. EFFECT OF 17ALPHA-METHYL-5BETA-DIHYDROTESTOSTERONE ON CLINICAL COURSE AND HORMONAL EXCRETION.
Topics: 17-Ketosteroids; Androgens; Breast; Breast Neoplasms; Creatine; Creatinine; Desoxycorticosterone; Di | 1963 |
CALCIUM AND PHOSPHATE METABOLISM IN PATIENTS WITH DISSEMINATED BREAST CANCER: EFFECT OF ANDROGENS AND OF PREDNISONE.
Topics: Androgens; Blood Chemical Analysis; Bone and Bones; Breast; Breast Neoplasms; Calcium; Calcium, Diet | 1963 |
GLOMERULAR FILTRATION IN DISSEMINATED BREAST CANCER.
Topics: Androgens; Breast Neoplasms; Creatine; Creatinine; Estrogens; Humans; Hydrocortisone; Hypophysectomy | 1964 |
[REABSORPTION OF PHOSPHORUS IN THE RENAL TUBULES IN NONPARATHYROGENOUS DISEASES].
Topics: Adenoma; Bone Neoplasms; Breast Neoplasms; Creatine; Creatinine; Denmark; Diagnosis, Differential; H | 1964 |
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine | 1964 |
Renal tubular dysfunction and urinary zinc excretion in breast cancer patients treated with anthracycline-based combination chemotherapy.
Topics: Acetylglucosaminidase; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; C | 2004 |
The treatment of hypercalcemia with inorganic phosphate salts.
Topics: Adult; Aged; Blood Urea Nitrogen; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Creatine; Fem | 1967 |
Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma.
Topics: Adult; Aspartic Acid; Brain Neoplasms; Breast Neoplasms; Carcinoma; Choline; Contrast Media; Creatin | 1994 |
Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Death; Colonic Neo | 1996 |
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain; Brain Diseases; B | 1998 |
Magnetic resonance spectroscopy and breast cancer.
Topics: Biopsy, Needle; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Choline; Creatine; F | 1998 |
Miltefosine: new preparation. Solution for cutaneous application.
Topics: Administration, Cutaneous; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Clinical Trial | 1998 |
Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity.
Topics: Biological Transport; Breast Neoplasms; Cell Division; Creatine; Creatine Kinase; Creatinine; Female | 1999 |
Early morning hydroxyproline excretion in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Creatine; Female; Humans; Hydroxyproline; Neoplasm Metastasis; Tim | 1976 |
Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling.
Topics: Biomarkers; Breast Neoplasms; Calcium; Creatine; Cyclic AMP; Humans; Hypercalcemia; Kidney Tubules; | 1990 |
Urinary hydroxyproline excretion in patients with cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Creatine; Female; Humans; | 1969 |